Overview
LenioBio develops ALiCE®, a scalable eukaryotic cell-free protein expression system that produces complex proteins within 24 hours. The platform enables rapid manufacturing of vaccine-relevant proteins, antibodies, virus-like particles, and membrane proteins, reducing traditional production timelines by approximately 75%. ALiCE® supports applications from research through clinical-scale biomanufacturing, with yields up to 3mg/ml and seamless scaling from microliter to liter volumes.
Frequently asked questions
- What proteins can ALiCE® produce?
- ALiCE® produces complex proteins including membrane proteins, antibodies, multispecific antibodies, virus-like particles (VLPs), vaccine-relevant antigens, and proteins requiring post-translational modifications. The system can express full-length, folded, and functional proteins.
- How fast is protein production with ALiCE®?
- ALiCE® produces proteins in 24 hours for standard applications. For vaccine development, the platform can produce vaccine-relevant proteins in 20-40 days, approximately one-quarter the time required by traditional cell culture methods.
- Does ALiCE® scale from research to manufacturing?
- Yes, ALiCE® is the only eukaryotic cell-free system designed to scale reliably from early research through large-scale production. It supports scalable expression from microliter to liter volumes, streamlining the full drug development process.
- What is the basis of LenioBio's cell-free technology?
- ALiCE® is based on a Nicotiana tabacum (tobacco) BY-2 lysate, a plant-based eukaryotic cell-free protein expression system that harnesses cellular RNA and protein synthesis machinery without living cells.
- Who are LenioBio's manufacturing partners?
- LenioBio collaborates with ReciBioPharm, a global contract development and manufacturing organization (CDMO), to scale protein manufacturing capabilities. The company also partners with Avantor for distribution across Europe.